Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on March 17, 2008

Hypertension. 2008
Published online before print March 17, 2008, doi: 10.1161/HYPERTENSIONAHA.107.105718
A more recent version of this article appeared on May 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
51/5/1372    most recent
HYPERTENSIONAHA.107.105718v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Molnar, G. A.
Right arrow Articles by Fiebeler, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Molnar, G. A.
Right arrow Articles by Fiebeler, A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Related Collections
Right arrow Other Vascular biology
Right arrow Cell signalling/signal transduction

Submitted on November 21, 2007
Revised on December 19, 2007

Glucocorticoid-Related Signaling Effects in Vascular Smooth Muscle Cells

Gergö A. Molnar; Carsten Lindschau; Galyna Dubrovska; Peter R. Mertens; Torsten Kirsch; Marcus Quinkler; Maik Gollasch; Stefanie Wresche; Friedrich C. Luft; Dominik N. Muller; and Anette Fiebeler*

From the Medical Faculty of the Charité (G.A.M., G.D., S.W., F.C.L., D.N.M., A.F.), Experimental and Clinical Research Center and Max Delbrück Center, Franz Volhard Clinic, HELIOS Klinikum-Berlin, Berlin, Germany; Department of Nephrology and Clinical Immunology (P.R.M.), University Hospital Rheinisch-Westfälische Technische Hochschule-Aachen, Aachen, Germany; Department of Internal Medicine-Nephrology (C.L., T.K.), Hannover University Medical School, Hannover, Germany; 2nd Department of Medicine and Nephrological Center (G.A.M.), University of Pecs, Pecs, Hungary; Section Nephrology/Intensive Care (M.G.), Campus Virchow, Charité, Berlin, Germany; Section Clinical Endocrinology (M.Q.), Campus Mitte, Charité, Berlin, Germany.

* To whom correspondence should be addressed. E-mail: fiebeler{at}charite.de.

Abstract—Mineralocorticoid receptor blockade protects from angiotensin II–induced target-organ damage. 11{beta}-Hydroxysteroid dehydrogenase type 2 protects the mineralocorticoid receptor from activation by glucocorticoids; however, high glucocorticoid concentrations and absent 11{beta}-hydroxysteroid dehydrogenase type 2 in some tissues make glucocorticoids highly relevant mineralocorticoid receptor ligands. We investigated the effects of corticosterone (10-6 to 10-12 mol/L) on early vascular mineralocorticoid receptor signaling by Western blotting, confocal microscopy, and myography. Corticosterone initiated extracellular signal–regulated kinase 1/2 phosphorylation in rat vascular smooth muscle cells at ≥10-11 mol/L doses. Protein synthesis inhibitors had no effect, indicating a nongenomic action. Corticosterone also stimulated c-Jun N-terminal kinase, p38, Src, and Akt phosphorylation at 15 minutes and enhanced angiotensin II–induced signaling at 5 minutes. A specific epidermal growth factor receptor blocker, AG1478, as well as the Src inhibitor PP2, markedly reduced corticosterone-induced extracellular signal–regulated kinase 1/2 phosphorylation, as did preincubation of cells with the mineralocorticoid receptor antagonist spironolactone. Silencing mineralocorticoid receptor with small interfering RNA abolished corticosterone-induced effects. Corticosterone (10-9 mol/L) enhanced phenylephrine-induced contraction of intact aortic rings. These effects were dependent on the intact endothelium, mineralocorticoid receptor, and mitogen-activated protein kinase kinase 1/extracellular signal-regulated kinase signaling. We conclude that corticosterone induces rapid mineralocorticoid receptor signaling in vascular smooth muscle cells that involves mitogen-activated protein kinase kinase/extracellular signal–regulated kinase–dependent pathways. These new mineralocorticoid receptor–dependent signaling pathways suggest that glucocorticoids may contribute to vascular disease via mineralocorticoid receptor signaling, independent of circulating aldosterone.


Key words: corticosterone • angiotensin • phenylephrine • mineralocorticoid receptor • epidermal growth factor receptor